Recurrent gene mutation in AML, such as FLT3-ITD and RUNX1, can contribute to pathogenesis and disease progression, thus influencing the outcomes (Marcucci et al., 2011; Heath et al., 2017; Daver et al., 2019). The gene discussed is FLT3; the disease is acute myeloid leukemia.